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HIV-1 reverse transcriptase (RT)-associated RNase H activity is an essential function in viral genome retrotranscription. RNase
H is a promising drug target for which no inhibitor is available for therapy. Diketo acid (DKA) derivatives are active site Mg2-
binding inhibitors of both HIV-1 RNase H and integrase (IN) activities. To investigate the DKA binding site of RNase H and the
mechanism of action, six couples of ester and acid DKAs, derived from 6-[1-(4-fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-
5-hexenoic acid ethyl ester (RDS1643), were synthesized and tested on both RNase H and IN functions. Most of the ester deriva-
tives showed selectivity for HIV-1 RNase H versus IN, while acids inhibited both functions. Molecular modeling and site-di-
rected mutagenesis studies on the RNase H domain demonstrated different binding poses for ester and acid DKAs and proved
that DKAs interact with residues (R448, N474, Q475, Y501, and R557) involved not in the catalytic motif but in highly conserved
portions of the RNase H primer grip motif. The ester derivative RDS1759 selectively inhibited RNase H activity and viral replica-
tion in the lowmicromolar range, making contacts with residues Q475, N474, and Y501. Quantitative PCR studies and fluores-
cence-activated cell sorting (FACS) analyses showed that RDS1759 selectively inhibited reverse transcription in cell-based assays.
Overall, we provide the first demonstration that RNase H inhibition by DKAs is due not only to their chelating properties but
also to specific interactions with highly conserved amino acid residues in the RNase H domain, leading to effective targeting of
HIV retrotranscription in cells and hence offering important insights for the rational design of RNase H inhibitors.
Since the discovery of 3=-azidothymidine, the HIV-1-coded re-verse transcriptase (RT) has been the main target for drug
treatments that have successfully turned the lethal progression to
AIDS into a chronic disease (1, 2). However, the emergence of side
effects of long-term therapy and the selection of drug-resistant
viral strains demand novel anti-HIV agents, possibly targeting vi-
ral functions not yet explored (3, 4). RT plays a crucial role in viral
replication, carrying out the synthesis of integration-competent
double-stranded DNA starting from the ()-strand RNA viral
genome. Retrotranscription proceeds through an RNA/DNA hy-
brid intermediate, whose RNA must be removed to allow ()-
strand DNA synthesis. This RNA removal is performed by the
RT-associated RNase H function through a sequence of highly
specific hydrolytic events. Since the RNase H function is essential
for viral replication (5), it has been explored as a drug target, and
a number of RNaseH inhibitors (RHIs) have been reported (6–8).
RHIs can be classified based on their binding sites, i.e., (i) RHIs
that coordinate the two Mg2 catalytic cofactors at the RNase H
active site, such asN-hydroxyimides (9), hydroxytropolones (10),
hydroxypyrimidines (11), naphthyridinones (12), nitrofuran-2-
carboxylic acid carbamoylmethyl esters (13), hydroxyquinolino-
nes (14), and thiocarbamates and triazoles (15), or (ii) allosteric
RHIs, such as vinylogous ureas (16), thienopyrimidinones (17),
hydrazones (18), anthraquinones (19), isatines (20, 21), and pro-
penones (22).
Despite this large number of identified scaffolds, currently no
RHI has successfully reached clinical approval. In fact, efforts
aimed to developMg2-binding RHIs have been hampered by the
topology of the RNase H active site, which is relatively large and
shallow in comparison with closely related virus-encoded poly-
nucleotidyl transferases such as HIV-1 DNA polymerase and in-
tegrase (IN) (23, 24), hampering the identification of a suitable
binding pocket near the catalytic region. In fact, in all cocrystal-
lized structures ofHIV-1RT/RNaseH and active site RHIs (12, 24,
25), the RHIs exhibited binding poses showing a large part of their
structures extending out of the protein domain. Therefore, be-
sides the coordination with the two catalytic Mg2 ions, the in-
hibitors established very few contacts with RNase H binding site
residues (26), providing poor information about the binding in-
teractions. This lack of information hampered further optimiza-
tion of lead RHIs to achieve greater potency and selectivity, which
are required for detailed characterization of the mechanisms of
action in cell-based assays.
Diketo acid (DKA) derivatives are among the first compounds
reported to bind the Mg2 cofactors in the active site of influenza
virus endonuclease (27), HIV-1 IN (28), and HIV-1 RNase H (29,
30). Among them, 6-[1-(4-fluorophenyl)methyl-1H-pyrrol-2-
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yl)]-2,4-dioxo-5-hexenoic acid ethyl ester (RDS1643) was the first
ligand proven to be able to inhibit both HIV-1 RNase H in bio-
chemical assays and viral replication in cell culture (30). Recently,
a new series of pyrrolyl DKAs that are active against both HIV-1
IN and RNase H has been reported (31), with acidic compounds
being more effective with IN and ester counterparts being active
with both enzymes, with no particular difference. Moreover, a
recent study on RHI effects on and binding to prototype foamy
virus (PFV) RT showed a putative RDS1643 binding region in the
PFV RNase H active site and suggested, given the high level of
structural similarity between PFV and HIV-1 RNase H domains,
the possibility that RDS1643 could show similar interactions with
the HIV-1 RNase H domain (32).
Herein, we report the synthesis of six new ester/acid couples of
pyrrolyl DKAs and assays aiming to identify the molecular deter-
minants required for DKAs for selective interactions with the
HIV-1 RT RNase H domain and to clarify whether the catalytic
region of RNase H can offer additional anchor points that might
be targeted by drugs. Subsequent molecular docking and site-di-
rected mutagenesis studies allowed us to establish a well-defined
interaction pattern for DKA derivatives with highly conserved
amino acid residues in the RNaseH active site, proving differences
in binding orientations between ester and acid derivatives that
allowed rationalization of their different inhibition profiles. Fur-
thermore, we show that the derivative RDS1759 effectively and
selectively inhibited HIV reverse transcription in cells. Overall,
these findings provide relevant insights for rational drug design of
RHIs.
MATERIALS AND METHODS
Chemistry. Details concerning the synthesis and characterization proce-
dures for all new compounds can be found in the supplemental material.
Site-directed mutagenesis. Alanine substitutions were introduced
into the p66 HIV-1 RT subunit, using the QuikChange protocol (Agilent
Technologies, SantaClara, CA), in a p(His)6-tagged p66/p51HIV-1HXB2
RT-prot plasmid kindly provided by Stuart Le Grice (NCI Frederick).
Expression and purification of recombinant HIV-1 RTs. (His)6-
tagged p66/p51 HIV-1 RTs were expressed in Escherichia coli strain M15
containing the p6HRT-prot vector and grown to an optical density at 600
nm (OD600) of 0.7, and expression was induced for 4 h with isopropyl
-D-1-thiogalactopyranoside (IPTG) at 1.7 mM. Protein purification was
carried out with a BioLogic LP system (Bio-Rad) with a combination of
immobilized metal ion affinity chromatography and ion-exchange chro-
matography. Cell pellets were resuspended in lysis buffer (50mM sodium
phosphate [pH 7.8], 0.5 mg/ml lysozyme), the mixture was incubated on
ice for 20 min, 0.3 M NaCl (final concentration) was added, and the
mixture was sonicated and centrifuged for 1 h at 30,000 g. The super-
natant was loaded onto a Ni2-Sepharose column that was preequili-
brated with loading buffer (50 mM sodium phosphate [pH 7.8], 0.3 M
NaCl, 10% glycerol, 10 mM imidazole) and was washed thoroughly with
wash buffer (50 mM sodium phosphate [pH 6.0], 0.3 M NaCl, 10% glyc-
erol, 80mM imidazole). RTwas subjected to gradient elutionwith elution
buffer (wash buffer with 0.5 M imidazole). Fractions were collected, and
protein purity was checked by SDS-PAGE and found to be greater than
90%. Enzyme-containing fractions were pooled, diluted 1:1 with dilution
buffer (50 mM sodium phosphate [pH 7.0], 10% glycerol), and then
loaded onto a HiTrap Heparin HP column (GE Healthcare Life Sciences)
preequilibrated with 10 column volumes of loading buffer 2 (50 mM
sodium phosphate [pH 7.0], 10% glycerol, 150 mM NaCl). The column
was then washed with loading buffer 2, and RT was subjected to gradient
elution with elution buffer 2 (50 mM sodium phosphate [pH 7.0], 10%
glycerol, 150 mMNaCl). Purified protein was dialyzed and stored in buf-
fer containing 50mMTris HCl (pH 7.0), 25mMNaCl, 1 mMEDTA, and
50% glycerol. Catalytic activities and protein concentrations were deter-
mined. Enzyme-containing fractions were pooled, and aliquots were
stored at80°C.
Expression and purification of recombinant HIV-1 IN. HIV-1 IN
was expressed essentially as reported previously (33). Briefly, His-tagged
IN was produced in E. coli BL21-CodonPlus (DE3)-RIPL (Agilent, Santa
Clara, CA) and purified under nondenaturing conditions. Protein pro-
duction was induced to OD600 of 0.6 to 0.8 by adding IPTG to a concen-
tration of 0.5 mM. Culture mixtures were incubated for 3 h at 37°C and
then centrifuged at 1,100 g for 20min at 4°C. Cells were resuspended in
buffer A (50 mMTris-HCl [pH 8], 1 MNaCl, 4 mM -mercaptoethanol)
and lysed by passage through a French press. The lysate was centrifuged
(30 min at 12,000 g at 4°C), and the supernatant was filtered (pore size,
0.45 m) and incubated with nickel-nitrilotriacetic acid-agarose beads
(Qiagen, Venlo, The Netherlands) for at least 2 h at 4°C. The beads were
washed with buffer A and then with buffer A supplemented with 80 mM
imidazole. His-tagged proteins were then eluted from the beads with buf-
fer A supplemented with 1 M imidazole and 50 M zinc sulfate and were
then dialyzed overnight against 20mMTris-HCl (pH 8), 1MNaCl, 4mM
-mercaptoethanol, 10% glycerol. Aliquots of the purification products
were rapidly frozen and stored at80°C.
HIV-1 DNA polymerase-independent RNase H activity determina-
tion.Wild-type (wt) andmutantHIVRT-associatedRNaseH activity was
measured as described previously (34). Briefly, RT-associated RNase H
activity was measured in a 100-l reaction volume containing 50 mM
Tris-HCl (pH 7.8), 6 mM MgCl2, 1 mM dithiothreitol (DTT), 80 mM
KCl, and 0.25 M hybrid RNA/DNA (5=-GTTTTCTTTTCCCCCCTGA
C-3=-fluorescein/5=-CAAAAGAAAAGGGGGGACUG-3=-dabcyl). The
reaction mixture was incubated for 1 h at 37°C, the reaction was stopped
with the addition of 50 l of 0.5 M EDTA (pH 8.0), and products were
quantified with a Victor 3 plate reader (Perkin) with excitation at 490 nm
and emission at 528 nm.Different amounts of enzymes were used accord-
ing to the linear ranges of the dose-response curves, i.e., 20 ng wt, 37.5 ng
R448A, 62.5 ngN474A, 300 ngQ475A, 1g Y501A, and 75 ngR557ARTs.
All experiments were performed at least three times.
HIV-1 RDDP activity determination. The HIV-1 RT-associated
RNA-dependent DNA polymerase (RDDP) activity was measured as de-
scribed previously (34), in the presence of different amounts of enzymes
according to the linear ranges of the dose-response curves, i.e., 20 ng wt,
30 ngR448A, 30 ngN474A, 100 ngQ475A, 30 ng Y501A, and 30 ngR557A
RTs. All experiments were performed at least three times.
Evaluation of DNA polymerase-independent RNase H and RDDP
kinetic efficiencies. Kinetic analysis of the DNA polymerase-indepen-
dent RNase H and RDDP activities was performed with Lineweaver-
Burke plots, using SigmaPlot 10 software. Velocity () was expressed as
fmol/min.
HIV-1 IN activity determination. The strand-transfer reaction was
performed as described previously (35). Oligonucleotides HIV-1B (5=-T
GTGGAAAATCTCTAGCA-3=) and HIV-1A (5=-ACTGCTAGAGATTT
TCCACA-3=) (Eurogentec) were used for the strand-transfer reaction.
HIV-1B was radiolabeled with T4 polynucleotide kinase (Biolabs) and
[-32P]ATP (3,000Ci/mmol; Amersham) andwas purified on a Sephadex
G-10 column (GE Healthcare). The strand-transfer reaction was carried
out at 37°C in buffer containing 10mMHEPES (pH 7.2), 1mMDTT, and
7.5 mM MgCl2 or MnCl2, in the presence of 12.5 nM DNA substrate.
Products were loaded on denaturing 18% acrylamide/urea gels. Gels were
analyzed with aMolecular Dynamics Storm PhosphorImager, and results
were quantified with ImageQuant 4.1 software.
Cells and viruses. MT4 and 293T cells were cultured in RPMI 1640
medium and Dulbecco’s modified Eagle’s medium (DMEM), respec-
tively. Both media were supplemented with 10% fetal calf serum (FCS).
HIV-1 stocks were prepared by transfecting 293T cells with the HIV-1
molecular clone derived from pNL4-3 (	env viruses) (36); wt NLENG1-
ES-IRES encodes the wt IN. Pseudotyping of	env viruses was performed
by cotransfection of 293T cells with a vesicular stomatitis virus glycopro-
Corona et al.
6102 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 D
ecem
ber 19, 2014 by UNIVERSITA CAG
LIARI
http://aac.asm
.org/
D
ow
nloaded from
 
tein (VSV-G) plasmid using the calcium phosphate method. Viral super-
natants were filtered (pore size, 0.45 m) and frozen at 80°C. HIV-1
p24gag antigen contents in viral inocula were determined by enzyme-
linked immunosorbent assay (Perkin-Elmer Life Sciences). A total of 120
ng of p24gag antigen per 106 cells, corresponding to a multiplicity of in-
fection (MOI) of 0.3, was used for infection. When required, cells were
treated with raltegravir (RAL) (100 nM) or efavirenz (EFV) (100 nM).
Flow cytometric analysis was performed with a FACSCalibur flow cytom-
eter (BD Bioscience), and results were analyzed using ImageQuant soft-
ware.
Cytotoxicity assay. The proliferation of MT4 cells was measured by
seeding 1 104 cells/well on 96-well plates in 100 l of RPMI 1640 me-
dium with FCS (10%), penicillin (100 U/ml), and streptomycin (200 g/
ml), as described previously (34).
Molecular modeling. The 3-dimensional structures of DKAs were
generated with the Maestro Build Panel (Schrodinger, New York, NY), as
described previously (37). The crystal structure of the full-length HIV-1
RT in complex with a naphthyridinone inhibitor bound to the RNase H
active site (PDB accession no. 3LP1) was selected for docking studies. The
missing residue R557, which is part of the RNase H active site, was mod-
eled using the coordinates of the crystal structure with PDB accession no.
3K2P. The receptor was then prepared with the Protein PreparationWiz-
ard of the Schrödinger 2012 molecular modeling package, as described
previously (38). Docking studies were finally carried out with the grid-
based program Glide 5.8 (Schrödinger) (38). For the grid generation, a
box of 20 Å by 20 Å by 20 Å, centered on the active site Mg2 ions, was
created. The standard precisionmode of theGlideScore functionwas used
to score the binding poses obtained. The force field used for the docking
wasOPLS-2005 (39). All of the pictureswere renderedwith PyMOL (www
.pymol.org) and Maestro (Schrödinger).
Quantificationof viralDNAgenomes.Quantitative PCR (qPCR)was
performed as described previously (40). Briefly, MT4 cells were infected
and treated at time zero and 10 h postinfection (p.i.) in the presence of
inhibitors RDS1759 and RDS1760 at concentrations of 10 M, using as
controls RAL and EFV at concentrations of 200 nM and 100 nM, respec-
tively. Two million to five million cells were collected at each time point.
Cells were washed in phosphate-buffered saline (PBS), and dry cell pellets
were frozen at80°C until use. DNA from infected cells was purifiedwith
aQIAampDNABloodminikit (Qiagen), according to themanufacturer’s
instructions. Quantification of total viral DNA, 2-long terminal repeat
circle (2-LTRc), and integrated DNAs was performed with a LightCycler
instrument (Roche Diagnostics) using the second-derivative-maximum
method provided by the LightCycler quantification software (version 3.5;
Roche Diagnostics). Amplification of the -globin gene (two copies per
diploid cell) was performed to normalize the results, using commercially
available materials (control DNA kit; Roche Diagnostics). The quantifi-
cation results for 2-LTRc, total HIV-1 DNA, and integrated HIV-1 DNA
were expressed as copy numbers per g DNA.
RESULTS
Inhibition of HIV-1 RT-associated DNA polymerase-indepen-
dent RNase H activity. Starting from the DKA prototype
RDS1643 (30), we synthetized six ester/acid couples of pyrrolyl
DKAs designed to define the structure-activity relationships
within this series. In particular, we (i) put halogen, alkyl, or alkoxy
substituents at different positions on the benzyl ring, (ii) shifted
the diketo ester/acid chain from position 2 to position 3 of the
pyrrole moiety, and (iii) added a further phenyl ring in position 4
of the pyrrole ring (Fig. 1). The newly synthesized derivatives were
tested for their ability to inhibit the HIV-1 RT-associated DNA
polymerase-independent RNase H and RNA-dependent DNA
polymerase (RDDP) functions as well as IN strand-transfer activ-
ity in biochemical assays and viral replication in cell-based assays
(Table 1). All of the DKAs inhibited RNase H activity, with the
ester derivatives generally beingmore potent than their acid coun-
terparts (Table 1). This effect was more evident for derivatives
RDS1759, RDS2291, andRDS2400, which showed 50% inhibitory
concentration (IC50) values for RNase H activity of 7.3, 8.2, and
11.2 M, respectively, while being completely inactive as IN in-
hibitors at up to 100 M. Conversely, all of the acid derivatives
weremore potent than their ester counterparts as IN inhibitors, as
reported previously (31). Interestingly, some derivatives, inde-
pendent of their acid/ester structure, also inhibited RDDP activ-
ity. In particular, RDS1822 was active with respect to both RT-
associated activities and IN activity in the same range of
concentrations.
To further investigate their modes of action, all of the deriva-
tives were tested for their ability to bind Mg2 ions, based on the
DKA UV spectra recorded in the absence and in the presence of 6
mM MgCl2, and all were shown to be able to bind the ions (data
not shown). Finally, cell-based assays revealed that four of the six
new ester/acid couples were able to inhibit viral replication, with
only the RDS2400/2401 and RDS2291/2292 derivatives being to-
tally inactive (Table 1).
Molecular docking. Molecular docking studies were per-
formed to elucidate the binding modes of the newly synthesized
DKA derivatives at the RNase H active site. The docking results
suggested that the investigated ligands shared similar binding
modes, although some differences in the interaction patterns es-
tablished by ester and acid derivatives were observed. Among our
set of RNase H inhibitors, we decided to consider primarily the
binding modes of compounds RDS1643/RDS1644 and RDS1711/
FIG 1 Chemical structures of newly synthesized DKA derivatives.
DKAs Target Highly Conserved Residues of HIV-1 RNase H
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RDS1712,which, althoughnot displaying the bestRNaseH/IN selec-
tivity profiles, represented the most structurally different couples of
ester and acid derivatives. In this view, the structural diversity of the
selected compounds should result in different predicted ligand-en-
zyme interactions, so as to suggest themutation of different residues
and lead to experimental data with high information gain.
Docking of derivatives RDS1643/RDS1644 and RDS1711/
RDS1712 suggested that both ester and acid DKAs coordinate the
two catalytic Mg2 ions; however, they adopt slightly different
binding orientations due to the steric hindrance of the ethyl sub-
stituent of the ester derivatives (Fig. 2A and C). Besides the metal
cofactor coordination, both RDS1643 and RDS1644 interact with
a number of RNase H active site residues. In particular, the diketo
ester branch of RDS1643 H-bonds with the N474 side chain and
establishes lipophilic interactions with the A445 and I556 residues
through its ethyl substituent, while the DKA moiety of RDS1644
forms a salt bridge with the R557 side chain. Additionally, the
benzyl ring of both the ester and the acid forms parallel-displaced
interactions with the Y501 side chain, while the pyrrole ring of
RDS1643 can establish further lipophilic interactionswith theC-

and C- carbons of the Q475 residue. Finally, docking of the ester
derivative RDS1711 (Fig. 2E) indicates that this compound is able
to form an additional cation- interaction with the R448 guani-
dinium group through its benzyl substituent, while the phenyl at
TABLE 1 Biological effects of DKA derivatives on HIV-1 RT-associated RNase H and IN activities and HIV-1 replication
Compound RNase H IC50
a (M) RDDP IC50
b (M) IN IC50
c (M) HIV-1 EC50
d (M) MT4 CC50
e (M) SIf
RDS1643 8.6 1.3 50 21 3 15.5 50 3.22
RDS1644 16.1 2.3 50 0.16 0.03 0.29 50 172
RDS1711 8.0 0.2 50 21 12 4.3 26.9 6.3
RDS1712 7.7 0.5 50 1.55 0.15 17.2 50 2.9
RDS1759 7.3 0.1 50 100 2.10 50 23.8
RDS1760 19.2 0.8 40 3 0.59 0.77 15.4 50 3.2
RDS1822 6.3 1.8 31 9 42 28 3.4 14.1 4.14
RDS1823 87 5 50 0.59 0.19 3.2 50 15.6
RDS2291 8.2 1.2 12.1 2.5 100 15.4 15.4
RDS2292 19.3 2.6 25 2 26 4 25.5 25.5
RDS2400 11.2 1.1 26 1 100 50 50
RDS2401 28 5 50 28 3 50 50
a Compound concentration (mean standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%.
b Compound concentration (mean standard deviation) required to inhibit HIV-1 RT RDDP activity by 50%.
c Compound concentration (mean standard deviation) required to inhibit HIV-1 IN activity by 50%.
d EC50, compound concentration required to decrease viral replication in MT-4 cells by 50%.
e CC50, compound concentration required to reduce infected MT-4 cell viability by 50%.
f SI, selectivity index (CC50/EC50 ratio).
FIG 2 Binding modes of DKA derivatives at the HIV-1 RNase H active site. (A, C, E, and G) Stick models of RDS1643 (A), RDS1644 (C), RDS1711 (E), and
RDS1712 (G), represented as yellow, orange, light green, and dark green sticks, respectively. The receptor is shown as a gray cartoon. Amino acids involved in
ligand binding are highlighted as sticks. The active site Mg2 ions are represented as magenta spheres. (B, D, F, and H) Corresponding two-dimensional
representations of DKA-RNase H interactions. Red and blue sticks represent oxygen and nitrogen atoms, respectively, and dashed lines represent hydrogen
bonds.
Corona et al.
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position 4 on the pyrrole ring interacts with the Y501 side chain
(Fig. 2E and F). Conversely, the corresponding acid RDS1712 is
not predicted to interact with the R448 side chain, while its 4-phe-
nyl substituent interacts with the Y501 side chain and itsN-benzyl
group contacts residueW535 (Fig. 2G andH).We also performed
molecular docking of derivatives RDS1759, RDS2291, and
RDS2400, obtaining the same docking patterns (see Fig. S2 in the
supplemental material).
Catalytic efficiency ofmutant HIV-1 RTs. Based on the inter-
action patterns predicted by docking calculations, we selectively
mutated into Ala residues R448, N474, Q475, Y501, and R557
within the sole p66 subunit of HIV-1 RT. It is important to note
that the N474, Q475, and Y501 residues are highly conserved,
playing crucial roles as part of the RNase H primer grip (31). In
fact, amino acid substitutions of these residues have been reported
to reduce the HIV-1 replication rate drastically (41) and to affect
RNase H enzymatic activity strongly (42). To determine whether
the selected mutated RTs were suitable for quantitative assays, we
performed kinetic analyses of both their RNase H and RDDP cat-
alytic efficiencies (Fig. 3). Consistent with previous observations
(42), all of the RNase H primer grip-mutated RTs showed drasti-
cally reduced but still measurable catalytic efficiency for RNase H
activity (Table 2). In contrast, the kcat/Km ratios of the R448A and
R557A RTs showed no reductions. Finally, none of the amino
acid-substituted RTs showed significant changes in the RT-asso-
ciated RNA-dependent DNApolymerase (RDDP) function, com-
pared with wt RT, with the sole exception of Q475A RT, which
showed a kcat/Km ratio of 8.1 for RDDP function.
Evaluation of effects of DKA derivatives on mutant RTs. In
order to experimentally verify the binding model suggested by
computational studies, DKA derivatives were tested for their abil-
ity to inhibit the RNase H function of all RTs with amino acid
substitutions, using the RHI -thujaplicinol (BTP) (10) as a con-
trol (Table 3). Results showed drastic reductions of inhibitory
potency (generally more than 1 order of magnitude) of all DKAs
when tested onN474ARTRNaseH, confirming the crucial role of
this residue for DKA binding. The loss of the H-bond with the
N474 side chainmight explain the lower activities observed for the
ester derivatives. However, the increases in the IC50 values ob-
served also for the acid ligands suggest an additional functional/
structural role for N474 at the RNase H active site. In the case of
the R557A RT, only moderate increases in IC50 values were ob-
served, which were greater for the acid derivatives than for their
ester counterparts. Indeed, as predicted by docking calculations,
acid derivatives make a salt bridge with the R557 side chain in the
wt RT that cannot be established in the R557Amutant RT (Fig. 2D
and H).
When the DKAs were assayed with the Q475A RT, the de-
creases in potency shown by the ester derivatives were generally
greater than those observed for the corresponding acids. In par-
ticular, the esters RDS1643, RDS1822, RDS2400, RDS1759, and
RDS2291 exhibited IC50s at least 10 times higher than those for wt
FIG 3 Comparison of the kinetics of polymerase-independent RNase H and RDDP activities of HIV-1 RTmutants. (A) The polymerase-independent RNase H
cleavage activity for all HIV-1 RT mutants was measured in 100-l reaction volumes containing increasing amounts of RNA/DNA hybrid substrate and fixed
ratios of enzymes, according to the linear ranges of the dose-response curves. (B) The RDDP activity was measured in 25-l volumes containing 100 M
poly(A)-oligo(dT), increasing concentrations of dTTP, and fixed ratios of enzymes, according to the linear ranges of the dose-response curves. The kinetic
analyses were performed with Lineweaver-Burke plots of both RNase H and RDDP activities., wt RT; Œ, R448A RT;o, N474A RT; , Q475A RT; , Y501A
RT; , R557A RT. Error bars represent standard deviations calculated from three independent determinations.
TABLE 2 Comparison of kinetics of wt and mutant HIV-1 RT DNA polymerase-independent RNase H and RDDP activities
RT
RNase H activity RDDP activity
kcat (min
1) Km (nM) kcat/Km ratio kcat (min
1) Km (nM) kcat/Km ratio
wt 112 1 126 5 0.89 23 1 0.94 0.03 25
R557A 25 3 41 1 0.60 19.2 1.5 0.94 0.10 20
R448A 44 9 85 22 0.52 14.6 1.4 0.90 0.01 16
Q475A 10.7 1.9 100 11 0.11 8.4 0.5 1.04 0.18 8
N474A 2.6 0.5 30 0.1 0.08 23 1 1.19 0.03 19
Y501A 0.25 0.07 29 9 0.008 20 1 1.34 0.03 15
DKAs Target Highly Conserved Residues of HIV-1 RNase H
October 2014 Volume 58 Number 10 aac.asm.org 6105
 o
n
 D
ecem
ber 19, 2014 by UNIVERSITA CAG
LIARI
http://aac.asm
.org/
D
ow
nloaded from
 
RT, while their acid counterparts exhibited 3- to 5-fold lower
IC50s, with the sole exception of RDS1823, which showed an 11-
fold IC50 decrease. According to docking results, the Q475A sub-
stitution significantly reduces the interaction surface accessible to
ester derivatives within the RNase H active site. Conversely, the
Q475A amino acid substitution can allow acid derivatives to in-
teract more tightly with the Y501 side chain through the benzyl
group (or through the 4-phenyl substituent for RDS1712).
The results with Y501A RT showed significant decreases in
potency for all ester derivatives as well as for their acid counter-
parts, with the exception of compounds RDS1644 and RDS2401.
This result could suggest that the Y501A substitutionmodifies the
interactions with the adjacentQ475 by inducing a conformational
rearrangement of the protein binding site that can be hardly noted
in docking experiments with rigid protein models. Finally, the
R448A substitution affected the potency of RNase H inhibition by
RDS1711 (12-fold increase in its IC50) (Table 3), in agreement
with the docking results for RDS1711 and RDS1712, showing that
the former but not the latter can establish cation- interactions
with the R448 side chain of the wt RT through the benzyl group
(Fig. 2C and D).
Characterization of mechanisms of DKA inhibition in cell-
based assays. Among the newly synthesized DKA derivatives,
RDS1759 proved to be the sole compound able to selectively in-
hibitHIV-1 replication in cell-based assays and the RNaseH func-
tion in biochemical assays without affecting either the RT-associ-
ated RDDP function (Table 1) or the IN strand-transfer function.
Therefore, we chose the ester/acid DKA couple RDS1759/
RDS1760 to investigate in more detail their mechanisms of action
in cell-based assays, and fluorescence-activated cell sorting
(FACS) andqPCRanalyseswere performed to detectwhich step of
viral replication was targeted. MT4 cells were infected with the
NLENG1-ES-IRESwt virus containing a green fluorescent protein
(GFP) reporter system and were treated with 10 M concentra-
tions of RDS1759 and RDS1760 DKAs at the time of infection or
10 h postinfection (p.i.), since this time point is considered to
occur at the end of the reverse transcription window (37). High
mean fluorescence (HMF) and low mean fluorescence highlight
expression from integrated viral DNA and unintegrated viral
DNA, respectively, as described previously (36). Sampleswere col-
lected and analyzed by FACS analysis at 48 and 72 h p.i., quanti-
fying (i) the percentage of emitting GFP (eGFP) cells, indicating
the amount of infected cells, which is reduced overall by reverse
transcription inhibitors such as EFV; and (ii) the percentage of
HMF, indicating the amount of integrated DNA, which is selec-
tively affected by integration process inhibitors such as RAL (Fig.
4A to E). FACS analysis showed an RDS1759 inhibition pattern
analogous to that observed for the nonnucleoside inhibitor EFV;
in fact, RDS1759 reduced the percentage of eGFP cells by 68% and
33% at 48 and 72 h p.i., respectively (Fig. 4D). Surprisingly, inhi-
bition of retrotranscription by RDS1759 was found to be time
dependent, since it was significantly reduced at 72 h p.i. In order to
confirm this mechanism of action, drugs were added at 10 h p.i.,
and results showed strong impairment of the effect of RDS1759 on
the percentage of eGFP cells (only 30% inhibition). In contrast,
RDS1760 showed an HIV-1 inhibition pattern similar to that of
the IN inhibitor raltegravir (RAL), suggesting that RDS1760
mainly affects the integration step of the viral replication process.
Next, we used qPCR to determine the total viral DNA and
2-LTRc DNA amounts during the early phases of viral replication
in the presence of the two DKAs. First, compounds were added at
the time of infection andDNA samples were collected after 4, 6, 8,
10, 24, and 48 h (Fig. 5A and B). Second, DKAs were added at 10 h
postinfection (p.i.) and DNA samples were collected after 24 and
48 h (Fig. 5C and D). 2-LTRc accumulation has been described
when HIV-1 integration is impaired (43), and results showed that
RDS1760 followed the RAL profile of 2-LTR accumulation after
24 and 48 h, when added either at the time of viral infection or at
10 h p.i. Moreover, RDS1760 caused a 30% decrease in the total
amount of viral DNA, greater than the decrease observed with
RAL treatment. Therefore, RDS1760 may partially inhibit reverse
transcription also, although it appears to target mainly integra-
tion. Conversely, the derivative RDS1759 induced a strong reduc-
tion in the formation of total viral DNA and followed the EFV
profile until the time point at 10 h. In fact, such reduction was
partially reversed at 24 h. Consistent with the absence of IN inhi-
bition, RDS1759 showed no accumulation of 2-LTRc DNA, com-
pared to untreated control samples. These results clearly indicate
that RDS1760 primarily acts on IN, while RDS1759 selectively
inhibits reverse transcription in a time-dependent manner. To
confirm this hypothesis, we determined the viral inhibition rate by
RDS1759 at 24 and 48 h, observing an important shift in the 50%
TABLE 3 Inhibition of HIV-1 RT-associated RNase H activity of mutated HIV-1 RTs by DKAs
Compound
IC50 (M) (% activity)
a
R448A R557A N474A Q475A Y501A
RDS1643 10.9 2.1 17.0 2.3 80 6 92 12 100 (86)
RDS1644 19.3 1.6 45 1 100 (55) 5.5 1.5 11.6 5.1
RDS1711 100 2 50 5 100 (100) 100 (83) 100 (100)
RDS1712 8.1 0.3 19.6 3.8 100 (62) 100 (80) 100 (80)
RDS1822 6.5 3.5 17.4 3.4 94 10 71 4 100 (76)
RDS1823 88 6 100 (68) 100 2 7.4 1.5 6.4 1.6
RDS2400 15.1 2.9 25 5 63 12 100 (55) 100 (70)
RDS2401 25 2 61 6 100 (65) 28 4 30 7
RDS1759 8.6 0.1 16.2 3.0 89 6 96 1 100 (100)
RDS1760 20 2 63 1 100 (79) 6.3 2.3 100 (80)
RDS2291 10.0 2.0 20 5 100 (56) 100 (76) 100 (85)
RDS2292 27 3 58 3 100 (84) 3.4 0.6 100 (100)
BTP 0.15 0.02 0.22 0.05 0.09 0.01 0.19 0.03 0.07 0.005
a IC50, compound concentration (mean standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%. Numbers in parentheses indicate the percent
enzyme activity measured in the presence of 100 M compound.
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effective concentration (EC50) from 0.17M to 1.16M (see Fig.
S2 in the supplementalmaterial). This effect could be due either to
cellular metabolism or to fast dissociation of the ligand from the
target. To clearly distinguish between these two possibilities, we
determined, at 24 and 48 h p.i., the amounts of integrated viral
DNA with RDS1759 added 12 h before infection, at the time of
infection, or 12 h p.i. and also added twice (at infection and 12 h
p.i.), using RAL as a control (Fig. 6). RDS1759 addition 12 h be-
FIG 4 Inhibition of HIV-1 replication by DKAs. MT4 cells were infected with NLENG1-ES-IRES wt virus containing a GFP reporter system. (A to E) Samples were
analyzed 48 h postinfection to quantify the amount of emitting GFP cells (eGFP) versus the GFP intensity of emission, categorized as low intensity (M1), indicating
expression from unintegrated viral DNA, and high intensity (M2), indicating integrated viral DNA expressing GFP. (A) InfectedMT4 cells. (B)MT4 cells treated with
100 nMEFV. (C)MT4 cells treated with 200 nMRAL. (D)MT4 cells treated with 10MRDS1759. (E)MT4 cells treated with 10MRDS1760. (F to I) Samples were
analyzed 48hours p.i. (gray) and 72hours p.i. (black) to quantify the percentage of total (M1 andM2) emittingGFP cells (F andG) and the percentage ofHMF(M2) (H
and I) normalized to the percentage of the untreated control sample.Drugs (10MRDS1759, 10MRDS1760, 100nMEFV, and 200nMRAL)were added at the time
of infection (F andH) or 10 h p.i. (G and I). The experiment was performed three times (error bars represent standard deviations).
FIG 5 qPCR kinetics of total and 2-LTRc DNA forms during a single round of HIV replication in the presence of inhibitors. MT4 cells were infected with HIV-1
in the absence () or in the presence of 10 MRDS1759 (Œ), 10 MRDS1760 (), 500 nM RAL (o), or 100 nM EFV (), added at infection (A and B) or 10
h p.i. (C and D). Samples were analyzed for total viral DNA and 2-LTRc at different p.i. time points. The experiment was performed three times (error bars
represent standard deviations). All samples were standardized and quantified relative to known standards, as described in Materials and Methods.
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fore infection led to consistent decreases in viral inhibition, con-
firming the hypothesis of its cellular metabolism or degradation.
In agreement with this hypothesis, the potency of RDS1759 was
maximal when it was added at the time of infection or was added
twice (at the time of infection and at 12 h p.i.); when it was added
at 12 h p.i., inhibition also occurred but to a lesser extent. Taken
together, these data demonstrate that RDS1759 efficiently targets
HIV-1 reverse transcription.
DISCUSSION
DKAs have been reported to be the first active site agents that can
effectively inhibit both HIV-1 RNase H and IN functions, or only
one of them, in the lowmicromolar range and that can also inhibit
HIV-1 replication in cell-based assays (30, 44). Despite these
promising results, the binding modes of DKAs within the RNase
H domain have not been further characterized, and no DKA de-
rivative was further investigated to confirm whether it actually
inhibited reverse transcription in cell-based assays. A recent study
onDKA inhibition of bothRNaseH and IN functions showed that
IN function was preferentially inhibited by acid analogs, while
RNase H function was equally inhibited by both ester and acid
derivatives (31). The different activity profiles of ester and acid
DKAs for IN may arise from the different electrostatic properties
of the HIV-1 RNase H and IN active sites. In particular, in the
RNase H active site, four catalytic acid residues (D443, E478,
D498, and D549) completely neutralize the four positive charges
of the two active site Mg2 ions. On the other hand, the IN active
site is positively charged, since only three acidic residues (D64,
D116, and D152) counterbalance the four positive charges of the
two catalyticMg2 ions.With this perspective, negatively charged
acidic compounds may bind more favorably to HIV-1 IN than to
the RNase H active site (24). Starting from these results, in the
present study we synthesized 6 new couples of diketo ester and
DKA derivatives with various structural features, to be used as
chemical tools in the characterization of RNase H bindingmodes.
In agreement with previous studies (30, 31), among the designed
molecules all of the acids weremore potent against IN, while three
esters (RDS1759, RDS2291, and RDS2400) proved to selectively
inhibit RNase H activity, compared to IN. Interestingly, a few
DKA derivatives were also able to inhibit RDDP activity. In par-
ticular, while most of these compounds (i.e., RDS2291, RDS2292,
RDS2400, and RDS2401) did not inhibit viral replication,
RDS1822 was active on both RT-associated activities and IN ac-
tivity in the same range of concentrations and inhibited HIV rep-
lication. Further studies should be performed to characterize the
RDDP inhibition by DKAs and to better define the RDS1822
mode of action on viral replication. Molecular modeling studies
on the RT RNase H domain predicted that our DKAs would in-
teract with a number of residues surrounding the RNase H active
site, i.e., R448, N474, Q475, Y501, and R557, most of which are
highly conserved (45) as part of the RNase H primer grip motif
(41, 42, 46). This is a singular pattern that is interesting for the
large number of residues involved and is in agreement with recent
observations on the interaction of RDS1643 and the PFV domain
of RNase H (32). In fact, all of the crystal structures of RT/RNase
H prototypes solved in complexes with active site RHIs show the
ligands coordinating the metal cofactors (25, 47) while exhibiting
an orientation of binding that does not allow extended secondary
interactions with amino acid side chains. The only exceptions are
represented by hydroxytropolones and naphthyridinones (25,
48), with the latter being found to be sandwiched by a loop con-
taining residues A538 and H539 on one side and N474 on the
opposite side (12). Interestingly, our modeling studies propose
different binding orientations for ester and acid DKAs in the
RNase H domain, due to the steric hindrance of the alkyl substit-
uent on the DKA branch of ester derivatives, which mainly influ-
ence the interactions with Q475 and R448. To confirm the calcu-
lation outcomes, all of the residues identified as significant for
DKA binding were point mutated to alanine. It was reported pre-
viously that amino acid substitution of N474, Q475, and Y501 to
Ala modifies RNase H cleavage specificity and can alter the Kd
related to DNA polymerase substrates (42), reducing viral titra-
tion in cell-based assays up to 10-fold (41). In agreement with
these studies, our evaluation of the catalytic efficiencies of both
RNase H and RDDP enzymatic activities showed decreases in the
FIG 6 Effects of the time of RDS1759 addition on HIV-1 replication. HIV-1-infected MT4 cells were treated with 10 MRDS1759, 200 nM RAL, or 100 nM EFV at
different timepoints.Thexaxis shows the time(h)of compoundaddition.Sampleswerecollectedat24and48h, and integratedviralDNAwasmeasured.All resultswere
quantified by qPCR and normalized to values for infected untreated cells. The experiment was performed three times (error bars represent standard deviations).
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kcat/Km ratios of RNase H activity for all RNase H primer grip
mutants. However, these mutants fully conserved their efficien-
cies for RDDP function. Biochemical assays of our DKAs with
each mutated RT confirm the interaction patterns indicated by
docking studies, validating the PFV RNase Hmodel (31) as a tool
to characterize HIV-1 RHIs. Biochemical results also confirm the
hypothesis of different binding orientations for esters and acids. In
particular, in the presence of theQ475A substitution, the RNaseH
inhibitory potency is significantly decreased (with respect to wt RT)
in the case of esterDKAderivatives, while it is increased in the case of
their acidcounterparts.Furthermore, inagreementwith thedocking-
predicted interaction between R448 and ester RDS1711, this com-
pound proved to be inactive with the R448A RT, while no change in
IC50 was observed for the acid counterpart RDS1712.
The biochemical results for our new set of DKA derivatives
revealed that the ester RDS1759 could selectively inhibit RNase H
activity while being ineffective with both IN and RDDP functions,
while its acid counterpart RDS1760 was shown to preferentially
target HIV-1 IN. RDS1759 also inhibited HIV-1 replication in
cell-based assays, with no evident toxic effects.Monitoring of early
viral DNA product formation by FACS and qPCR showed that
RDS1759 could selectively target the reverse transcription process
in cell-based assays, although time-dependent decay of the inhi-
bition of viral replication was observed. Preincubation in cell cul-
ture before viral infection compromised the efficacy of RDS1759
against HIV-1, while chronic exposure to the ligand completely
restored the inhibition of viral replication. These results suggest
that at least partial intracellular ligand inactivationmight occur. It
is noteworthy that the hypothesis that esterases may be involved,
generating the acid counterpart, is not supported by the occur-
rence of late effects related to the inhibition of integration, such as
2-LTRc DNA accumulation, which still occur for the RDS1760
derivative at 48 h p.i. The more lipophilic nature of the ester DKA
with respect to its acid counterpart might suggest instead better
diffusion in other cellular compartments. Overall, while this time-
dependent effect of RDS1759 prevented its use to select drug-
resistant HIV-1 strains, the further development of RDS1759
analogs selective for RNase H inhibition and lacking this time-
dependent effect will allow the selection of resistant virus to con-
firm the amino acid residues involved in the binding to RT.
In conclusion, RDS1759 is the first compound, to the best of
our knowledge, that has been definitively proven to inhibit HIV-1
proliferation by inhibiting the genomic RNA hydrolysis by RT.
Unlike previously reported RHIs, RNase H inhibition by this
compound, as well as by the other DKA derivatives presented in
this study, involves interactions not only with Mg2 but also with
highly conserved residues within the RNaseH domain, thus offer-
ing important insights for rational optimization of RNaseH active
site inhibitors as new potential drugs for anti-HIV-1 treatment.
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